Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study

By Whitehead Robert   McCoy Sheryl   Macdonald John   Rivkin Saul   Neubauer Marcus   Dakhil Shaker   Lenz Heinz-Josef   Tanaka Michael   Abbruzzese James  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 335-341

Springer Publishing Company

Access to resources Recommend Favorite

Farnesyl Protein Transferase Inhibitor ZARNESTRA™ R115777 - History of a Discovery

By  

Current Topics in Medicinal Chemistry, Vol. 3, Iss. 10, 2003-06 ,pp. : 1095-1102

Bentham Science Publishers

Access to resources Recommend Favorite

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study

By Whitehead Robert   Benedetti Jacqueline   Abbruzzese James   Ardalan Bach   Goodwin J.   Balcerzak Stanley   Samlowski Wolfram   Lenz Heinz-Josef   Macdonald John  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 335-341

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

By Renouf Daniel  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 779-786

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

By Yana Takashi   Negoro Shunichi   Takada Minoru   Yokota Soichiro   Takada Yoshiki   Sugiura Takahiko   Yamamoto Hidehiko   Sawa Toshiyuki   Kawahara Masaaki   Katakami Nobuyuki   Ariyoshi Yutaka   Fukuoka Masahiro  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 253-258

Springer Publishing Company

Access to resources Recommend Favorite